Koen Augustyns

List of Publications by Year in Descending Order

184 papers	5,030 citations	41 h-index	58 g-index
209 ext. papers	5,729 ext. citations	4.9 avg, IF	5.06 L-index

#	Paper	IF	Citations
184	Targeting ferroptosis protects against experimental (multi)organ dysfunction and death.. *Nature Communications*, **2022**, 13, 1046	17.4	6
183	and Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. *Frontiers in Chemistry*, **2021**, 9, 640566	5	2
182	Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats. *Pharmaceutics*, **2021**, 13,	6.4	2
181	The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. *Frontiers in Pharmacology*, **2021**, 12, 682065	5.6	1
180	Strecker-Derived Methodology for Library Synthesis of -Acylated Aminonitriles. *ACS Omega*, **2021**, 6, 1328-1338	3.9	3
179	Lead Optimization of Phthalazinone Phosphodiesterase Inhibitors as Novel Antitrypanosomal Compounds. *Journal of Medicinal Chemistry*, **2020**, 63, 3485-3507	8.3	2
178	Preclinical Evaluation of a Novel F-Labeled dTCO-Amide Derivative for Bioorthogonal Pretargeted Positron Emission Tomography Imaging. *ACS Omega*, **2020**, 5, 4449-4456	3.9	5
177	Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs. *Trends in Pharmacological Sciences*, **2020**, 41, 209-224	13.1	43
176	Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-d-Ribose Oxidase (DprE1) Inhibitors. *Journal of Medicinal Chemistry*, **2020**, 63, 5367-5386	8.3	5
175	Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 958-967	5.1	6
174	A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. *Scientific Reports*, **2020**, 10, 17268	4.9	6
173	Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. *International Journal for Parasitology: Drugs and Drug Resistance*, **2019**, 9, 35-43	4	9
172	Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent ClpP Inhibitors. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	4
171	ClpP Protease, a Promising Antimicrobial Target. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	37
170	Caspase-3 probes for PET imaging of apoptotic tumor response to anticancer therapy. *Organic and Biomolecular Chemistry*, **2019**, 17, 4801-4824	3.9	13
169	The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. *Clinica Chimica Acta*, **2019**, 495, 154-160	6.2	10
168	Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers. *Bioorganic Chemistry*, **2019**, 87, 163-168	5.1	4

167	Efforts towards an On-Target Version of the Groebke-Blackburn-Bienaym[illegible](GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors. *Chemistry - A European Journal*, **2019**, 25, 12380-12393	4.8	8
166	Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). *ACS Medicinal Chemistry Letters*, **2019**, 10, 1173-1179	4.3	13
165	Selective Activity-Based Probes Targeting Fibroblast Activation Protein (FAP). *Proceedings (mdpi)*, **2019**, 22, 84	0.3	
164	Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging. *Nuclear Medicine and Biology*, **2019**, 76-77, 36-42	2.1	7
163	DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages. *Life Science Alliance*, **2019**, 2,	5.8	27
162	The effect of pharmacological inhibition of Serine Proteases on neuronal networks. *PeerJ*, **2019**, 7, e6796	3.1	3
161	[illegible]Amino Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. *Journal of Medicinal Chemistry*, **2019**, 62, 774-797	8.3	15
160	Tozasertib Analogues as Inhibitors of Necroptotic Cell Death. *Journal of Medicinal Chemistry*, **2018**, 61, 1895-1920	8.3	19
159	RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680). *Cell Death and Disease*, **2018**, 9, 211	9.8	16
158	Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. *Expert Opinion on Drug Discovery*, **2018**, 13, 477-488	6.2	12
157	Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. *European Journal of Medicinal Chemistry*, **2018**, 151, 18-26	6.8	6
156	Spectrophores as one-dimensional descriptors calculated from three-dimensional atomic properties: applications ranging from scaffold hopping to multi-target virtual screening. *Journal of Cheminformatics*, **2018**, 10, 9	8.6	8
155	Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. *British Journal of Pharmacology*, **2018**, 175, 3516-3533	8.6	19
154	Molecular biochemical characterization of selective glucocorticoid receptor activities of GSK866 analogues with cysteine reactive warheads. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO2-5-6	0	
153	Novel triazine dimers with potent antitrypanosomal activity. *European Journal of Medicinal Chemistry*, **2018**, 143, 306-319	6.8	12
152	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 11221-11249	8.3	16
151	Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. *Journal of Medicinal Chemistry*, **2018**, 61, 10126-10140	8.3	33
150	When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. *Cell Death and Differentiation*, **2017**, 24, 1100-1110	12.7	102

149	The power metric: a new statistically robust enrichment-type metric for virtual screening applications with early recovery capability. *Journal of Cheminformatics*, **2017**, 9, 7	8.6	15
148	ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice. *Biochemical Pharmacology*, **2017**, 138, 150-162	6	42
147	Evaluation of [F]BR420 and [F]BR351 as radiotracers for MMP-9 imaging in colorectal cancer. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2017**, 60, 69-79	1.9	5
146	Regulation of intestinal permeability: The role of proteases. *World Journal of Gastroenterology*, **2017**, 23, 2106-2123	5.6	75
145	Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. *European Journal of Medicinal Chemistry*, **2017**, 139, 482-491	6.8	7
144	Decreased levels of active uPA and KLK8 assessed by [In]MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy. *Epilepsia*, **2017**, 58, 1615-1625	6.4	5
143	Carboxylate isosteres for caspase inhibitors: the acylsulfonamide case revisited. *Organic and Biomolecular Chemistry*, **2017**, 15, 7456-7473	3.9	2
142	Virtual screening for inhibitors of the human TSLP:TSLPR interaction. *Scientific Reports*, **2017**, 7, 17211	4.9	6
141	Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. *Cell Death and Disease*, **2017**, 8, e2904	9.8	47
140	Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. *European Journal of Medicinal Chemistry*, **2017**, 125, 890-901	6.8	5
139	Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads. *Frontiers in Immunology*, **2017**, 8, 1324	8.4	7
138	Preclinical evaluation of [In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity. *Contrast Media and Molecular Imaging*, **2016**, 11, 448-458	3.2	11
137	Development of a novel antibody-tetrazine conjugate for bioorthogonal pretargeting. *Organic and Biomolecular Chemistry*, **2016**, 14, 7544-51	3.9	21
136	Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. *Pancreatology*, **2016**, 16, 829-38	3.8	17
135	Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry. *ChemMedChem*, **2016**, 11, 467-76	3.7	3
134	Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. *Journal of Medicinal Chemistry*, **2016**, 59, 6709-28	8.3	33
133	Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1159-68	5.1	5
132	Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-Deposition in the Brain. *Molecular Imaging and Biology*, **2016**, 18, 598-605	3.8	18

131	Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. *Journal of Medicinal Chemistry*, **2016**, 59, 2041-53	8.3	54
130	Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation. *MedChemComm*, **2016**, 7, 433-438	5	6
129	Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. *World Journal of Gastroenterology*, **2016**, 22, 10275-10286	5.6	27
128	In Vivo Amyloid-Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody. *Frontiers in Aging Neuroscience*, **2016**, 8, 67	5.3	2
127	Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5032-5038	2.9	7
126	Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. *European Journal of Medicinal Chemistry*, **2016**, 123, 631-638	6.8	9
125	The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics. *MedChemComm*, **2015**, 6, 1954-1958	5	8
124	Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging. *Nuclear Medicine and Biology*, **2015**, 42, 975-81	2.1	10
123	An essential signal peptide peptidase identified in an RNAi screen of serine peptidases of Trypanosoma brucei. *PLoS ONE*, **2015**, 10, e0123241	3.7	8
122	Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold. *Journal of Medicinal Chemistry*, **2015**, 58, 9238-57	8.3	24
121	Synthesis of Aziridino Amino Acid Derivatives and their Stereoselective Ring Transformation to 2-(Aminomethyl)-1-aminocyclopropanecarboxylic Acid Derivatives. *European Journal of Organic Chemistry*, **2014**, 2014, 1220-1226	3.2	5
120	Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. *Antiviral Research*, **2014**, 101, 113-21	10.8	19
119	Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. *Molecular Pharmaceutics*, **2014**, 11, 4405-14	5.6	12
118	Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. *International Journal of Pharmaceutics*, **2014**, 475, 238-44	6.5	21
117	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5241-8	3.4	7
116	In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain. *Nuclear Medicine and Biology*, **2014**, 41, 513-23	2.1	25
115	Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent. *Nuclear Medicine and Biology*, **2014**, 41, 477-87	2.1	12
114	Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). *Journal of Medicinal Chemistry*, **2014**, 57, 3053-74	8.3	103

113	Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. *MedChemComm*, **2014**, 5, 1700-1707	5	9
112	The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine. *Journal of Pharmaceutical Sciences*, **2014**, 103, 3696-3703	3.9	4
111	Resistance Profile of the Diaryltriazine Non-nucleoside Reverse Transcriptase Inhibitor and Candidate Microbicide UAMC01398. *AIDS Research and Human Retroviruses*, **2014**, 30, A212-A212	1.6	
110	Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders. *ChemBioChem*, **2014**, 15, 2238-47	3.8	7
109	Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. *Basic Research in Cardiology*, **2013**, 108, 350	11.8	61
108	Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. *ACS Medicinal Chemistry Letters*, **2013**, 4, 491-6	4.3	86
107	Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2038-47	5.1	16
106	Structures of purine nucleosidase from Trypanosoma brucei bound to isozyme-specific trypanocidals and a novel metalorganic inhibitor. *Acta Crystallographica Section D: Biological Crystallography*, **2013**, 69, 1553-66		9
105	Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA). *Bioorganic and Medicinal Chemistry*, **2012**, 20, 1557-68	3.4	16
104	Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3412-7	2.9	29
103	P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. *Journal of Medicinal Chemistry*, **2012**, 55, 9856-67	8.3	21
102	Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7174-8	2.9	8
101	Asymmetric synthesis of -chloro-,-diamino- and ,-aziridino--aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across -chloro-N-sulfinylimines. *Beilstein Journal of Organic Chemistry*, **2012**, 8, 2124-31	2.5	9
100	Reverse transcriptase inhibitors as microbicides. *Current HIV Research*, **2012**, 10, 27-35	1.3	15
99	Schistosomicidal and molluscicidal activities of aminoalkylamino substituted neo- and norneocryptolepine derivatives. *Pharmaceutical Biology*, **2012**, 50, 134-40	3.8	17
98	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. *Biological Chemistry*, **2011**, 392, 189-98	4.5	59
97	Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?. *Journal of Medicinal Chemistry*, **2011**, 54, 5737-46	8.3	43
96	Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). *Bioorganic and Medicinal Chemistry*, **2011**, 19, 5924-34	3.4	13

95	Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1900-8	5.9	25
94	The use of small volume TOC analysis as complementary, indispensable tool in the evaluation of photocatalysts at lab-scale. *Studies in Surface Science and Catalysis*, **2010**, 175, 321-324	1.8	1
93	Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?. *Current Medicinal Chemistry*, **2010**, 17, 2456-81	4.3	79
92	Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. *Peptides*, **2010**, 31, 585-91	3.8	37
91	The use of time-averaged 3JHH restrained molecular dynamics (tar-MD) simulations for the conformational analysis of five-membered ring systems: methodology and applications. *Journal of Computational Chemistry*, **2010**, 31, 561-72	3.5	10
90	-ketoheterocycles as inhibitors of Leishmania mexicana cysteine protease CPB. *ChemMedChem*, **2010**, 5, 1734-48	3.7	22
89	Influence of the Incorporation of 1-(2,3-Dideoxy- -D-Erythro-Hexopyranosyl)-Thymine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides. *Bulletin Des Soci s Chimiques Belges*, **2010**, 101, 119-130		25
88	Prolyl oligopeptidase of Trypanosoma brucei hydrolyzes native collagen, peptide hormones and is active in the plasma of infected mice. *Microbes and Infection*, **2010**, 12, 457-66	9.3	43
87	Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma. *Analytical Biochemistry*, **2010**, 396, 152-4	3.1	15
86	Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay. *Analytical Biochemistry*, **2010**, 403, 114-6	3.1	13
85	Design and evaluation of Trypanosoma brucei metacaspase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2001-6	2.9	16
84	Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. *Journal of Histochemistry and Cytochemistry*, **2009**, 57, 531-41	3.4	33
83	In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. *Biochemical Pharmacology*, **2009**, 77, 228-37	6	26
82	Synthesis of bicyclic N-arylmethyl-substituted iminoribitol derivatives as selective nucleoside hydrolase inhibitors. *ChemMedChem*, **2009**, 4, 249-60	3.7	12
81	Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2009**, 1794, 953-60	4	20
80	Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives. *Journal of Medicinal Chemistry*, **2009**, 52, 2979-88	8.3	54
79	Primary graft dysfunction in lung transplantation: the role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide. *Transplantation*, **2009**, 87, 1140-6	1.8	16
78	The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. *Transplantation*, **2009**, 88, 478-85	1.8	7

77	Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. *Peptides*, **2008**, 29, 1472-8	3.8	67
76	Structure-based protein engineering efforts with a monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties. *Protein Engineering, Design and Selection*, **2008**, 21, 257-66	1.9	11
75	Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. *Frontiers in Bioscience - Landmark*, **2008**, 13, 3558-68	2.8	20
74	Synthesis and biochemical evaluation of guanidino-alkyl-ribitol derivatives as nucleoside hydrolase inhibitors. *European Journal of Medicinal Chemistry*, **2008**, 43, 315-26	6.8	19
73	N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6752-63	3.4	27
72	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4159-62	2.9	52
71	Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4154-8	2.9	24
70	Synthesis of 6-methyl-6H-indolo[3,2-c]isoquinoline and 6-methyl-6H-indolo[2,3-c]isoquinoline: two new unnatural isoquinoline isomers of the cryptolepine series. *Tetrahedron*, **2008**, 64, 11802-11809	2.4	25
69	Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas. *International Journal of Pharmaceutics*, **2008**, 349, 234-40	6.5	57
68	Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. *Journal of Medicinal Chemistry*, **2007**, 50, 6638-46	8.3	43
67	Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. *Journal of Medicinal Chemistry*, **2007**, 50, 5568-70	8.3	44
66	The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2007**, 1774, 267-77	4	21
65	1,2,3-Triazolylalkylribitol derivatives as nucleoside hydrolase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2523-6	2.9	16
64	Dipeptidyl alpha-fluorovinyl Michael acceptors: synthesis and activity against cysteine proteases. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 6563-6	2.9	26
63	Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. *Current Topics in Medicinal Chemistry*, **2007**, 7, 621-35	3	47
62	Dipeptidyl peptidase 8/9-like activity in human leukocytes. *Journal of Leukocyte Biology*, **2007**, 81, 1252-6	6.5	51
61	Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. *Journal of Heart and Lung Transplantation*, **2007**, 26, 174-80	5.8	31
60	Dipeptidyl peptidase II and leukocyte cell death. *Biochemical Pharmacology*, **2006**, 72, 70-9	6	19

59	Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position. *Journal of Medicinal Chemistry*, **2006**, 49, 5785-93	8.3	28
58	Functional role of the conserved active site proline of triosephosphate isomerase. *Biochemistry*, **2006**, 45, 15483-94	3.2	34
57	CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. *Journal of Heart and Lung Transplantation*, **2006**, 25, 1109-16	5.8	21
56	Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation. *Transplantation Proceedings*, **2006**, 38, 3369-71	1.1	15
55	Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4777-9	2.9	7
54	The role of CD26/DPP IV in preservation of early pulmonary graft function. *Advances in Experimental Medicine and Biology*, **2006**, 575, 231-5	3.6	
53	In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII. *Advances in Experimental Medicine and Biology*, **2006**, 575, 73-85	3.6	5
52	Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. *Biochemical Journal*, **2005**, 388, 29-38	3.8	68
51	Search for substrates for prolyl oligopeptidase in porcine brain. *Peptides*, **2005**, 26, 2536-46	3.8	35
50	Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. *Journal of Medicinal Chemistry* , **2005**, 48, 1768-80	8.3	111
49	Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). *Biochemical Journal*, **2005**, 386, 315-24	3.8	62
48	The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. *Current Medicinal Chemistry*, **2005**, 12, 971-98	4.3	78
47	Substrate-assisted leaving group activation in enzyme-catalyzed N-glycosidic bond cleavage. *Journal of Biological Chemistry*, **2005**, 280, 14799-802	5.4	27
46	Lewis Acid Catalyzed Synthesis of N-Protected Diphenyl 1-Aminoalkylphosphonates. *Synthesis*, **2005**, 2005, 634-638	2.9	2
45	Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 1387-1407	6.8	39
44	Synthesis and electrophysiological characterization of cyclic morphiceptin analogues. *Biochemical Pharmacology*, **2004**, 67, 1887-95	6	3
43	Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. *Journal of Medicinal Chemistry*, **2004**, 47, 2906-16	8.3	39
42	Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator. *Journal of Medicinal Chemistry*, **2004**, 47, 2411-3	8.3	59

41	Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme. *Advances in Experimental Medicine and Biology*, **2003**, 524, 29-35	3.6	3
40	Fluorinated proline derivatives: potential transition state inhibitors for proline selective serine dipeptidases. *Tetrahedron Letters*, **2003**, 44, 969-972	2	22
39	Synthesis of (E)- and (Z)-fluoro-olefin analogues of potent dipeptidyl peptidase IV inhibitors. *Tetrahedron Letters*, **2003**, 44, 6231-6234	2	28
38	Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2875-8	2.9	41
37	Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases. *ACS Combinatorial Science*, **2003**, 5, 336-44		41
36	Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 499-510	6.8	56
35	Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. *Journal of Medicinal Chemistry*, **2003**, 46, 5005-14	8.3	36
34	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2553-6	2.9	23
33	Development of potent and selective dipeptidyl peptidase II inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2825-8	2.9	35
32	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: substitution of the glycine part. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2703-5	2.9	19
31	In vitro antioxidant profile of phenolic acid derivatives. *Free Radical Research*, **2002**, 36, 711-6	4	116
30	AN EFFICIENT SYNTHESIS OF ORTHOGONALLY PROTECTED SPERMIDINE. *Synthetic Communications*, **2002**, 32, 319-328	1.7	7
29	Polymer-assisted solution-phase parallel synthesis of dipeptide p-nitroanilides and dipeptide diphenyl phosphonates. *Tetrahedron Letters*, **2001**, 42, 9135-9138	2	9
28	Synthesis and evaluation of caffeic acid amides as antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 215-7	2.9	102
27	Structural determinants for ligand binding and catalysis of triosephosphate isomerase. *FEBS Journal*, **2001**, 268, 5189-96		33
26	Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. *Journal of Biological Chemistry*, **2001**, 276, 29839-45	5.4	223
25	Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. *Current Pharmaceutical Design*, **2001**, 7, 1117-41	3.3	71
24	Natural substrates of dipeptidyl peptidase IV. *Advances in Experimental Medicine and Biology*, **2000**, 477, 67-87	3.6	63

23	A New Approach Towards the Synthesis of 3-Amino-6-(hetero)arylpyridazines Based on Palladium Catalyzed Cross-coupling Reactions. *Tetrahedron*, **2000**, 56, 1777-1781	2.4	48
22	Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. *Journal of Biological Chemistry*, **1999**, 274, 3988-93	5.4	117
21	Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. *Journal of Medicinal Chemistry*, **1999**, 42, 1041-52	8.3	80
20	The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. *Current Medicinal Chemistry*, **1999**, 6, 311-27	4.3	27
19	The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors. *Current Medicinal Chemistry*, **1999**, 6, 311-327	4.3	104
18	Investigation on the stability of the Dde protecting group used in peptide synthesis: migration to an unprotected lysine. *Chemical Biology and Drug Design*, **1998**, 51, 127-33		20
17	Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design. *FEBS Journal*, **1997**, 250, 177-83		12
16	Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. *European Journal of Medicinal Chemistry*, **1997**, 32, 301-309	6.8	33
15	Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. *Biochimica Et Biophysica Acta - General Subjects*, **1996**, 1290, 76-82	4	29
14	Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase. *International Journal of Peptide Research and Therapeutics*, **1995**, 2, 198-202		9
13	A new synthetic method for proline diphenyl phosphonates. *Tetrahedron Letters*, **1995**, 36, 3755-3758	2	15
12	A Convenient One-Pot Preparation of Disubstituted Phosphinic Acids Derived from Simple Amino Acids and Proline. *Synthesis*, **1995**, 1995, 1074-1076	2.9	18
11	Synthesis of peptidyl acetals as inhibitors of prolyl endopeptidase. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 1265-1270	2.9	11
10	Synthesis of a new branched chain hexopyranosyl nucleoside: 1-[2?,3?-dideoxy-3?-C-(hydroxymethyl)-□D-erythro-pentopyranosyl]-thymine. *Tetrahedron*, **1994**, 50, 1189-1198	2.4	14
9	Hexopyranosyl-Like Oligonucleotides. *ACS Symposium Series*, **1994**, 80-99	0.4	14
8	Synthesis of 2,4-dideoxy-.beta.-D-erythro-hexopyranosyl nucleosides. *Journal of Organic Chemistry*, **1993**, 58, 2977-2982	4.2	37
7	Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides. *Nucleic Acids Research*, **1993**, 21, 4670-6	20.1	15
6	Acyclic oligonucleotides: possibilities and limitations. *Tetrahedron*, **1993**, 49, 7223-7238	2.4	48

5	Incorporation of hexose nucleoside analogues into oligonucleotides: synthesis, base-pairing properties and enzymatic stability. *Nucleic Acids Research*, **1992**, 20, 4711-6	20.1	61
4	Synthesis of 1-(2,4-dideoxy-Ð-erythro-hexopyranosyl)thymine and its incorporation into oligonucleotides. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 945-948	2.9	16
3	Influence of the incorporation of (S)-9-(3,4-dihydroxybutyl)adenine on the enzymatic stability and base-pairing properties of oligodeoxynucleotides. *Nucleic Acids Research*, **1991**, 19, 2587-93	20.1	47
2	Sugar Modified Oligonucleotides. *Nucleosides & Nucleotides*, **1991**, 10, 587-588		7
1	Synthesis and anti-HIV evaluation of 2Ş3Sdideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2Ş3Sdideoxynucleosides. *Journal of Medicinal Chemistry*, **1990**, 33, 1833-9	8.3	48